Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
8.29
+0.10 (1.22%)
At close: Sep 25, 2026, 4:00 PM EDT
8.12
-0.17 (-2.05%)
After-hours: Sep 25, 2026, 7:30 PM EDT
Atrium Therapeutics Revenue
In the year 2025, Atrium Therapeutics had annual revenue of $18.76M with 72.11% growth. Atrium Therapeutics had revenue of $860.00K in the quarter ending December 31, 2025, a decrease of -71.07%.
Revenue (ttm)
$18.76M
Revenue Growth
+72.11%
P/S Ratio
3.96
Revenue / Employee
n/a
Employees
n/a
Market Cap
141.81M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.76M | 7.86M | 72.11% |
| Dec 31, 2024 | 10.90M | 1.34M | 13.99% |
| Dec 31, 2023 | 9.56M | 336.00K | 3.64% |
| Dec 31, 2022 | 9.22M | -102.00K | -1.09% |
| Dec 31, 2021 | 9.33M | 2.54M | 37.41% |
| Dec 31, 2020 | 6.79M | 4.47M | 192.67% |
| Dec 31, 2019 | 2.32M | 1.94M | 511.87% |
| Dec 31, 2018 | 379.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 77.68M |
| Caribou Biosciences | 10.04M |
| Armata Pharmaceuticals | 5.54M |
| Korro Bio | 2.38M |
| Molecular Partners AG | 856.30K |
| Spruce Biosciences | 697.00K |
RNA News
- 5 days ago - Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 24 days ago - Atrium Therapeutics to Participate in Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 5 weeks ago - Atrium Therapeutics earns $15M milestone payment from Bristol Myers - TheFly
- 5 weeks ago - Atrium Therapeutics reports Q2 EPS ($1.18) vs (75c) last year - TheFly
- 6 weeks ago - Atrium Therapeutics Reports Second Quarter 2026 Financial Results - PRNewsWire
- 6 weeks ago - Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PRNewsWire
- 7 weeks ago - Atrium Therapeutics initiated with a Buy at H.C. Wainwright - TheFly